Radionuclide Injection Market Size, Share and Trends 2025 to 2034

Radionuclide Injection Market Size and Forecast 2025 to 2034

Radionuclide Injection Market is growing with rising demand in diagnostics and therapy. Explore regional trends, innovations, and competitive analysis, expanding at a CAGR of 10.04% from 2025 to 2034. The demand for diagnostic procedures like positron emission tomography (PET) scans has increased, driving the growth of the market for radionuclide injection. Advancements in nuclear medicine are expected to drive innovations in radionuclide injections, fostering market growth.

Radionuclide Injection Market Key Takeaways

• The radionuclide injection market is expected to grow at a CAGR of 10.04% from 2025 to 2034.
• North America dominated the radionuclide injection market in 2024.
• Asia Pacific is expected to grow at the fastest CAGR between 2025 and 2034.
• By type, the cancer segment contributed the biggest market share in in 2024.
• By type, the coronary artery disease segment is expected to grow at a significant CAGR in the coming years.
• By application, the hospitals segment held the largest share of the market in 2024.
• By application, the diagnostics center segment is projected to grow at a significant rate during the forecast period.

AI Impact on the Radionuclide Injection Market

Artificial Intelligence is a significant tool in improving process, monitoring, and drug discovery capabilities. AI influences radionuclide injection in nuclear medicine by improving image quality, diagnostic and therapeutic processes, and reducing radiation exposure. AI-driven monitoring helps to track patient outcomes and predict potential complications, optimizing the use of radionuclide injections. AI also helps in the development of novel and innovative radionuclide therapies. AI provides personalized and data-driven insights, enhancing treatment efficacy and patient outcomes. AI is creating transformative approaches in advancing critical therapy areas, including radionuclide injections.

Market Overview

The global radionuclide injection market has been witnessing significant growth, driven by advancements in diagnostics and therapeutic applications. Ongoing developments of advanced radiopharmaceutical technologies are fostering market growth. The increased incidence of chronic diseases like cancer, cardiovascular disease, and neurological disorders is driving demand for advanced radiopharmaceutical therapies, promoting the development of radionuclide injections. Additionally, regulatory frameworks and reimbursement policies for innovative diagnostics and therapies are expected to contribute to the growth of the market.

What are Recent Innovative Approaches in the Radionuclide Injection Market?

• In March 2025, the US Food and Drug Administration (FDA) approved Novartis’s Pluvicto, a radioligand therapy created for patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC).

(Source: https://www.novartis.com)

• In March 2025, the International Atomic Energy Agency (IAEA) highlighted its innovation to meet with increased demand for alpha-emitting radionuclides for targeted alpha therapy (TAT). 

(source: https://www.auntminnie.com)

What are the Key Factors Boosting the Growth of the Radionuclide Injection Market?

• Cancer and Neurological Disorder Prevalence: The increased prevalence of cancer and neurological disorders is driving the need for accurate diagnostic therapies, fostering demand for radionuclide injections.
• Innovative Approaches: Ongoing innovations in nuclear medicine and molecular imaging are enhancing radionuclide injection applications.
• Healthcare Expenditure: Expanding healthcare expenditure and government investments in developing novel therapies contribute to market growth.
• Demand for Personalized Medicines: The increased demand for personalized medicines and treatment plans opens up new avenues for radionuclide injection for target therapies.
• Regulatory Environments: Regulatory bodies, like the FDA, are supporting novel developments and the adoption of radionuclide injections, fostering market growth.

Market Scope

Market Dynamics

Drivers

Development of Next-Generation Therapies

With the increased incidence of cancer and neurological disorders, the demand for next-generation therapies is rising, which is expected to drive the growth of the radionuclide injection market. Ongoing developments of next-generation therapies, including radionuclide drug Conjugates (RDCs), Peptide Receptor Radionuclide Therapy (PRRT), Luthathera, Pulvicto, and advancements in radiopharmaceuticals are driving the advancements in radionuclide injections. Regulatory bodies are approving novel innovations in radiopharmaceuticals. Governments around the world have implemented positive reimbursement policies, enabling more access to next-generation therapies and contributing to market growth.

Restraint

High Cost and Side Effects

The high cost associated with radionuclide injections is a major factor restraining the growth of the market. The cancer treatment is expensive, making the adoption of high-cost radionuclide therapies a burden. Cancer patients seek affordable and more accessible treatments, which limits the adoption of radionuclide therapies. Long approval processes lead to high costs of radionuclide therapies and delay the introduction of new products. Additionally, potential side effects associated with radiation exposure increase concerns among healthcare providers and patients, limiting the adoption of radionuclide therapies.

Opportunity

Increasing Diagnostic and Therapeutic Applications in Nuclear Medicine

The expanding applications of radionuclide injections in diagnostics and therapeutics in nuclear medicine, especially for oncology, open new avenues for the growth of the radionuclide injection market. The increased prevalence of chronic diseases like cancer and cardiovascular diseases is driving the demand for advanced therapeutic and diagnostic solutions. This significantly prompts the development of advanced medicine procedures like PET and SPECT scans. In addition, continuous research & development efforts lead to improved radiopharmaceuticals, creating novel market opportunities.

Type Insights

The cancer segment dominated the market in 2024 due to the increased adoption of radionuclide injections in cancer treatments. The increased prevalence of cancer has boosted the demand for advanced diagnostic and therapeutic applications, including targeted radioligand therapies and radiopharmaceuticals. These therapies provide targeted treatment for various cancers. Ongoing advancements in research and clinical trials and the development of innovative radiopharmaceuticals support segmental growth.

The coronary artery disease segment is expected to grow at a significant CAGR in the coming years. The adoption of radionuclide injections for coronary artery disease has increased in recent years. Myocardial perfusion imaging (MPI) is mostly popular for assessing coronary artery disease. The radionuclide myocardial perfusion imaging (MPI) provides high diagnostic accuracy for the early detection of coronary artery disease. Additionally, the rising demand for non-invasive diagnostic tools is driving the adoption of radionuclide myocardial perfusion imaging (MPI).

Application Insights

The hospitals segment led the radionuclide injection market with the largest share in 2024. This is mainly due to the increased patient volumes undergoing cancer diagnostic and therapeutic procedures in hospitals. The advanced infrastructure of hospitals includes nuclear medicine departments and equipment for the administration and monitoring of radionuclide injections. The availability of trained healthcare professionals in hospitals drives patient preference for these settings. Additionally, rising government support and policies for hospital coverage are fostering patient treatment and diagnostic procedures in hospitals. 

The diagnostics center segment is projected to grow at a significant rate during the forecast period. Diagnostic centers have specialized equipment and healthcare professionals with expertise in nuclear medicine, which makes them the preferred choice for the administration of radionuclide injections. Diagnostic centers provide diagnostic radiopharmaceuticals used in imaging procedures like SPECT and PET to serve a large number of patients. The rising demand for cost-effective and efficient alternatives makes diagnostic centers more appealing to patients. 

Regional Insights

North America dominated the radionuclide injection market by holding the maximum share in 2024. This is mainly due to the region's high adoption rate of nuclear medicines, driven by well-established healthcare infrastructure, high prevalence of cancer and cardiovascular disease, and favorable regulatory environments. The adoption of PET and SPECT imaging has seen rapid growth in the region. North America is a hub for robust research and development and contributes to a strong focus on advanced nuclear medicine and radiopharmaceuticals.

The U.S. is a major player in the regional market due to its strong focus on innovation and the development of targeted therapies. The U.S. is the leader in the global radiopharmaceutical market. Increased cancer prevalence, strong research & development ecosystem, well-established healthcare infrastructure, favorable regulatory environment, high healthcare spending, and the existence of major key vendors, including GE HealthCare, Siemens Healthineers, and RayzeBio, are the factors contributing to market growth within the country.

Expanding Nuclear Medicine Infrastructure to Support Radionuclide Injection Market within Asia Pacific

Asia Pacific is projected to witness the fastest growth over the forecast period due to expanding nuclear medical infrastructure in the region, driven by increased numbers of chronic diseases, rising healthcare investments, government initiatives, and funding in improving cancer care and raising awareness and adoption of nuclear medicine technologies. The Government of Asia is investing heavily to enhance access to nuclear medicine technologies.

• For instance, in March 2025, DAE launched several radio-pharma products due to demand from the Board of Radiation and Isotope Technology (BRIT). The Board of Radiation and Isotope Technology (BRIT) consistently works to ensure the supply of radioisotopes and radiopharmaceuticals in India and carries out research and development for novel radiopharmaceuticals for cancer care. (source:https://www.pib.gov.in)

Which Country Dominates the Asia Pacific Radionuclide Injection Market?

China is projected to dominate the regional market due to its large population, rising healthcare spending, expanding pharmaceutical industry, and increased demand for advanced treatment solutions. The rising prevalence of cancer and the developing healthcare infrastructure are supporting China's market growth. Additionally, government initiatives and funding for improving cancer care and access to advanced medicines, including nuclear medicines, are fostering market growth. The rising demand for diagnostic and therapeutic applications of radionuclide injection is projected to expand China’s position in the market. 

Europe Radionuclide Injection Market & Trends

Europe has been witnessing steady growth. The prevalence of chronic disease has increased, driving the adoption of advanced imaging technologies like PET and SPECT. Regions' strong focus on enhancing nuclear medicine applications in diagnostics and therapy fosters market growth. Europe has been actively focusing on radiopharmaceutical supply chain vulnerabilities, including potential shortages, in 2025. Favorable regulations like EMA and HMA support assessing supply chains and novel radiopharmaceuticals in horizon scanning activities.

• In April 2025, new guidelines were issued by EMA and the Heads of Medicines Agencies (HMA) for radiopharmaceutical supply chain vulnerabilities. The guidance targets the enhancement of the complex supply chain for radiopharmaceuticals and medicines used for cancer. The shortage of radiopharmaceuticals emerged in different EU Member States, making significant expectations from this recommendation, issued through the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG).

 (Source: https://www.europeanpharmaceuticalreview.com)

Germany is a major player in the European radionuclide injection market. The growth of the market in the country is driven by the increased prevalence of cancer & cardiovascular disease and strong investments in nuclear medicine infrastructure. Favorable regulatory environments are accelerating approvals of novel nuclear medicine technologies and radiopharmaceuticals, contributing to market growth.

Radionuclide Injection Market Companies

• GE HealthCare
• Cardinal Health
• Curium
• Bayer AG
• Bracco Imaging S.p.A.
• Lantheus Holdings
• Siemens Healthineers
• Isotope JSC
• Jubilant Pharma
• Ntp Radioisotopes Soc Ltd.

Recent Developments

• In April 2025, Vivos Inc. announced new developments in its ongoing human clinical trial in India for RadioGel Precision Radionuclide Therapy. The RadioGel Precision Radionuclide Therapy is an FDA-approved device used for solid tumors. (source: https://www.globenewswire.com)
• In April 2025, Medi-Radiopharma (MRP), a company focused on nuclear medicine, celebrated its 30 years of innovation in nuclear medicine. The company announced the launch of its brand-new manufacturing facility, following FDA and EMA certification by the end of 2025. (Source: https://mediradiopharma.com)

Segments Covered in the Report

By Type

• Cancer
• Coronery Artery Disease
• Others

By Application

• Hospitals
• Clinics
• Diagnostics Center

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa